Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... ... The latest addition to the Mettler-Toledo PCE portfolio is the ... the pharmaceutical and healthcare industry can use the LSS to print track-and-trace labels for ... Station can be fully integrated into the production line and is also available as ...
(Date:9/3/2015)... Texas (PRWEB) , ... September 03, 2015 , ... ... suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not ... in late June 2015. Dr. McKenna treated Zack with precisely guided injections ...
(Date:9/3/2015)... 3, 2015  Guardant Health®, the leader in ... the performance and clinical utility of Guardant360® on ... and poster presentations at the International Association for ... on Lung Cancer. These abstracts were submitted by ... Davis; the University of Chicago; Sarah Cannon Research ...
(Date:9/3/2015)... Sept. 3, 2015  Vermillion, Inc. (NASDAQ: VRML ... today announced that Herbert Fritsche , Ph.D., the ... is the recipient of the 2015 Abbott Award, given ... for outstanding contributions to the field of basic or ... October 5 th in Zakopane, Poland ...
Breaking Biology Technology:Print and Verify Labels On The Production Line With New Label Serialization Stations 2Print and Verify Labels On The Production Line With New Label Serialization Stations 3UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2
... Biodiesel Standards, VANCOUVER, British Columbia, June 20 ... night,s final vote by the ASTM,International D02 Main ... for biodiesel blends. After more than five years ... fuel experts in the,blended fuel balloting process, ASTM ...
... 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... Drug Administration (FDA) review, the Company is ... intravenous administration of REOLYSIN(R) in,combination with paclitaxel ... neck cancers. The Principal Investigator is Dr. ...
... GlaxoSmithKline (NYSE:,GSK) today announced that the U.S. ... in combination with tamsulosin for the,treatment of symptomatic ... men over 50 years old. The new indication ... medicines treats the symptoms of,enlarged prostate more effectively ...
Cached Biology Technology:Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications 2Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 2FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 3FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate 4
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Saudi Arabia Biomedical Sensors market is estimated at $0.23 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/26/2015)... PUNE, India , August 26, 2015 ... (Two, Three, Four, and Five Factor), Application (Travel & ... and Geography - Global Forecast to 2020", published by ... 9.60 Billion by 2020, growing at a CAGR of ... 71 Tables and 82 F igures spread through ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... NEW YORK CITY A unique collaboration that leverages ... threatened marine environments is being launched today at upscale ... for Ocean Science ( http://www.pewoceanscience.org ) is pleased to ... five percent of the proceeds of its gorgeous new ...
... have discovered epigenetic changes (i.e. chemical changes to ... sequence) in individuals with schizophrenia and bipolar disorder. ... research, and this groundbreaking data may be a ... major psychosis. Dr. Arturas Petronis, senior scientist ...
... Board: CICI) -- Communication Intelligence Corporation ("CIC" or,the ... for,the financial industry and the recognized leader in ... the fourth quarter,and the year ended December 31, ... December 31, 2007 increased 63% to,$800,000, compared to ...
Cached Biology News:Pew Institute teams with Chantecaille Cosmetics to protect global marine life 2Epigenetic changes discovered in major psychosis 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 4Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 5Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2007 Results 6
... ion exchange media are ... high binding capacity. The ... a strong cation exchanger ... of 120 micrometers. Fully ...
...
... Aph-1a (Aph-1aL,S Loop 92-115), O2F1 Affinity ... a multiprotein complex consisting of presenilin, ... proteins are necessary for full proteolytic ... cleavage of a number of integral ...
... Epitope: A BALB/c mouse was ... Recommended Storage: Store vial at -20 C ... at -20 C or below for extended storage. ... Centrifuge product if not completely clear after standing ...
Biology Products: